EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Old tale new admirers, cetuximab maintenance in metastatic colorectal cancer: a systematic review and meta-analysis

Yici Yan, Zhenyi Lin, Jing Yuan, Weidong Gao, Chenxu Jiao, Leitao Sun, Xun Sun

Frontiers in Pharmacology · 03.06.2026 · 17

DOI: 10.3389/fphar.2026.1845800 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 03.06.2026. Verfasst von Yici Yan und 6 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background metastatic colorectal cancer (mCRC) represents a major global burden and the decision on whether to pursue maintenance with cetuximab (CET) remains controversial. Therefore, this meta-analysis was performed to assess the efficacy and safety of CET maintenance therapy.

Methods

After literature search of PubMed, Embase, Cochrane Library and Scopus from inception to March 2026, two investigators selected eligible studies and extracted relevant data. The key outcomes were progression-free survival (PFS) and overall survival (OS). A random-effects model was used for pooling. The relative risks (RRs) with 95% confidence interval (CI) of all-grade and high-grade (≥3) adverse effects (AEs) were used to study its safety. Heterogeneity was also investigated through subgroup and sensitivity analysis.

Results

A total of 6 studies with 727 patients were included. CET maintenance therapy prolonged the PFS (HR: 0.42, 95% CI: 0.27 to 0.57, P < 0.01) and OS (HR: 0.47, 95% CI: 0.19 to 0.74, P < 0.01) of mCRC patients. Subgroup analysis showed that Asian patients (HR: 0.53, 95% CI: 0.15 to 0.60, P = 0.010) received more survival benefit from CET maintenance therapy than non-CET therapy or observation. Although diarrhea and rash were more common, the RR of all-grade AEs revealed no statistical significance.

Conclusion

CET maintenance therapy may be associated with improved outcomes compared with observation, especially in Asian patients. But it may slightly increase treatment-related toxicities. Therefore, subsequent large sample, multi-center randomized controlled trials (RCTs) are needed to further verify our conclusions. Systematic Review Registration https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024513879 , identifier CRD42024513879.

Schlagwörter

Stichwörter der Autor:innen

cetuximabmaintenancemeta-analysismetastatic colorectal canceroverall survivalprogression-free survival

Autor:innen und Institutionen

  • The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.
  • Academy of Chinese Medical Science, Zhejiang Chinese Medical University, Hangzhou, China.
  • Key Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province, School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
  • Longyou Hospital of Chinese Medicine, Quzhou, Zhejiang, China.

Zitieren

APA

Yan, Y., Lin, Z., Yuan, J., Gao, W., Jiao, C., Sun, L., & Sun, X. (2026). Old tale new admirers, cetuximab maintenance in metastatic colorectal cancer: a systematic review and meta-analysis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1845800

Vancouver

Yan Y, Lin Z, Yuan J, Gao W, Jiao C, Sun L, et al. Old tale new admirers, cetuximab maintenance in metastatic colorectal cancer: a systematic review and meta-analysis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1845800

BibTeX
@article{Yan2026,
  author = {Yan, Yici and Lin, Zhenyi and Yuan, Jing and Gao, Weidong and Jiao, Chenxu and Sun, Leitao and Sun, Xun},
  title = {Old tale new admirers, cetuximab maintenance in metastatic colorectal cancer: a systematic review and meta-analysis},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1845800}
}
Kostenlos starten →